ReviewDrugs1994
Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.
Review in Drugs, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 97 citations in OpenAlex.
- Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.Intensive care medicine · 2003Trial
- Population pharmacokinetic study of teicoplanin in severely neutropenic patients.Antimicrobial agents and chemotherapy · 1996Trial
- From Access to Watch: An AWaRe-Oriented Evaluation of Antibiotic Prescribing in ASL Salerno.Antibiotics (Basel, Switzerland) · 2026Article
- A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.European journal of pharmacology · 2021Review
- Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.Bioorganic chemistry · 2021Review
- Advances in developing small molecule SARS 3CLTetrahedron · 2021Review
- Does the Addition of Poly(glycolide-co-lactide) to Teicoplanin-Containing Poly(methyl methacrylate) Beads Change the Elution Characteristics?Indian journal of orthopaedics · 2020Article
- Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues.Chemical reviews · 2017Review
- Clinical Pharmacology Studies in Critically Ill Children.Pharmaceutical research · 2017Review
- Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).The Journal of biological chemistry · 2016Article
- Effect of teicoplanin on the expression of c-myc and c-fos proto-oncogenes in MCF-7 breast cancer cell line.Advanced biomedical research · 2016Article
- The Prevention of Periprosthetic Joint Infections.The open orthopaedics journal · 2016Review
- Comparison of Borate Bioactive Glass and Calcium Sulfate as Implants for the Local Delivery of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus-Induced Osteomyelitis in a Rabbit Model.Antimicrobial agents and chemotherapy · 2015Article
- Is therapeutic drug monitoring of teicoplanin useful?Infection & chemotherapy · 2014Article
- A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Current drug metabolism · 2014Review
- In vitro and in vivo efficacies of teicoplanin-loaded calcium sulfate for treatment of chronic methicillin-resistant Staphylococcus aureus osteomyelitis.Antimicrobial agents and chemotherapy · 2010Article
- Review
- Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.Clinical pharmacokinetics · 2006Review
- Antibiotics in neonatal infections: a review.Drugs · 1999Review
- The therapeutic monitoring of antimicrobial agents.British journal of clinical pharmacology · 1999Review
Corrections and comments
- Erratum issued
- Erratum issued
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since an earlier review in the Journal substantial additional data have accumulated, further clarifying the in vitro activity, pharmacokinetic profile, clinical efficacy and tolerability of teicoplanin. Recent therapeutic trials confirm the efficacy of teicoplanin in the treatment of microbiologically confirmed Gram-positive infections, including septicaemia, endocarditis, and infections of skin and soft tissue, bone and joints, and the lower respiratory tract. As teicoplanin can be administered once daily intramuscularly as well as intravenously, it has potential for outpatient treatment of severe Gram-positive infections. Teicoplanin is appropriate as treatment of patients with fever and neutropenia, but there is still controversy over the timing for introduction of glycopeptide antibiotics into therapeutic regimens. Teicoplanin is generally reserved for secondary therapy of patients with documented bacteraemia who fail to respond to initial empirical antibiotic regimens, but probably should be part of the initial empirical regimen in the setting of a high incidence of methicillin-resistant staphylococci. Teicoplanin has a lower propensity than vancomycin to impair renal function when either drug is combined with an aminoglycoside, causes fewer anaphylactoid reactions, and appears to be of comparable efficacy. Thus, teicoplanin may be preferred to vancomycin in the treatment of Gram-positive infections, and where a glycopeptide antibiotic is deemed a necessary inclusion in a regimen for empirical treatment in patients with fever and neutropenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.